Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma

  title={Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma},
  author={John F. de Groot and Mark R. Gilbert and Kenneth D. Aldape and Kenneth R. Hess and Tamar Abu Hanna and Sandra Ictech and Morris D. Groves and Charles D. Conrad and Howard Colman and Vinay K. Puduvalli and Victor Levin and W. K. Alfred Yung},
  journal={Journal of Neuro-Oncology},
Targeting the epidermal growth factor receptor (EGFR) may be effective in a subset of glioblastoma patients. This phase II study assessed the clinical activity of erlotinib plus carboplatin and to determine molecular predictors of response. The primary endpoint was progression free survival (PFS). Patients with recurrent glioblastoma with no more than two prior relapses received carboplatin intravenously on day 1 of every 28-day cycle (target AUC of 6 mg × ml/min). Daily erlotinib at 150 mg/day… CONTINUE READING


Publications citing this paper.


Publications referenced by this paper.
Showing 1-10 of 35 references

Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26034

  • M Van Den Bent, A Brandes, +7 authors D Lacombe
  • Proc Am Soc Clin Oncol
  • 2007
1 Excerpt

Phase II study of erlotinib in recurrent GBM: molecular predictors of outcome

  • T Cloughesy, WA Yung, K Vredenberg
  • Am Soc Clin Oncol Annu Meet
  • 2005
1 Excerpt

Similar Papers

Loading similar papers…